medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2026, Number 2

<< Back

Dermatología Cosmética, Médica y Quirúrgica 2026; 24 (2)

Cutaneous adverse reactions associated with incretin-based therapies for weight loss: an emerging concern in the era of GLP-1 agonists

Rivas CN

Language: Spanish
References: 8
Page: 357-358
PDF size: 120.46 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weeklysemaglutide in adults with overweight or obesity. N Engl JMed. 2021;384:989-1002.

  2. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-ledweight management for remission of type 2 diabetes. Lancet.2018;391:541-551.

  3. Nauck MA, Meier JJ. Management of endocrine disease: GLP-1receptor agonists in diabetes and obesity. Lancet DiabetesEndocrinol. 2019;7:776-785.

  4. Davies MJ, Bergenstal R, Bode B, et al. Efficacy and safetyof semaglutide compared with other GLP-1 receptoragonists. Lancet Diabetes Endocrinol. 2017;5:275-286.

  5. Faillie JL. Case reports of hypersensitivity reactions associatedwith GLP-1 receptor agonists. Diabetes Care. 2014;37:e234-e235.

  6. Raschi E, Poluzzi E, Salvo F, et al. Adverse events withGLP-1 receptor agonists reported to pharmacovigilancesystems. Diabetes Care. 2013;36:e180.

  7. Drucker DJ. Mechanisms of action and therapeutic applicationof GLP-1 receptor agonists. Cell Metab. 2018;27:740-756.

  8. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versussemaglutide once weekly in patients with type 2 diabetes.N Engl J Med. 2021;385:503-515.




2020     |     www.medigraphic.com